BACKGROUND: Multiple drug resistance (MDR) greatly limits the efficacy of chemotherapy for colon cancer. An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to 'IL-24' here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin. However, the relatively low expression level of IL-24 mediated by a replication-deficient adenoviral vector hindered its clinical application. METHODS: To enhance IL-24-dependentreversion of the MDR phenotype, we utilized a conditionally replicative adenoviral vector, AdBB-IL24, to express IL-24 at a high level for more efficient MDR reversion. RESULTS: An enzyme-linked immunosorbent assay (ELISA) suggested conditionally replicative adenoviral vector-mediated IL-24 expression was elevated in comparison with that of a replication-deficient adenoviral vector, Ad-IL24. AdBB-IL24 was shown to reverse MDR in colon cancer cells more potently than Ad-IL24. The AdBB-IL24-induced MDR reversion was linked to reduced P-glycoprotein (Pgp) and breast cancer resistance protein 1 (BCRP1) expression. Consistently, 5-fluorouracil and doxorubicin induced more apoptosis in AdBB-IL24-infected colon cancer cells compared with that in the Ad-IL24-infected cells. A cell viability assay showed that AdBB-IL24 could enhance the growth-inhibitory effect of 5-fluorouracil and doxorubicin on colon cancer cells more effectively than Ad-IL24 in vitro. In a mouse model, we also found that the combination of 5-fluorouracil and doxorubicin with AdBB-IL24 completely inhibited the growth of colon cancer cells. CONCLUSION: We here provide evidence supporting conditionally replicative adenoviral vector-based gene therapy as a powerful strategy to enhance mda7/IL-24-dependent MDR reversion of colon cancer cells.
BACKGROUND: Multiple drug resistance (MDR) greatly limits the efficacy of chemotherapy for colon cancer. An adenovirus armed with Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24; abbreviated to 'IL-24' here) was shown to reverse the MDR of colon cancer cells to oxaliplatin and doxorubicin. However, the relatively low expression level of IL-24 mediated by a replication-deficient adenoviral vector hindered its clinical application. METHODS: To enhance IL-24-dependentreversion of the MDR phenotype, we utilized a conditionally replicative adenoviral vector, AdBB-IL24, to express IL-24 at a high level for more efficient MDR reversion. RESULTS: An enzyme-linked immunosorbent assay (ELISA) suggested conditionally replicative adenoviral vector-mediated IL-24 expression was elevated in comparison with that of a replication-deficient adenoviral vector, Ad-IL24. AdBB-IL24 was shown to reverse MDR in colon cancer cells more potently than Ad-IL24. The AdBB-IL24-induced MDR reversion was linked to reduced P-glycoprotein (Pgp) and breast cancer resistance protein 1 (BCRP1) expression. Consistently, 5-fluorouracil and doxorubicin induced more apoptosis in AdBB-IL24-infected colon cancer cells compared with that in the Ad-IL24-infected cells. A cell viability assay showed that AdBB-IL24 could enhance the growth-inhibitory effect of 5-fluorouracil and doxorubicin on colon cancer cells more effectively than Ad-IL24 in vitro. In a mouse model, we also found that the combination of 5-fluorouracil and doxorubicin with AdBB-IL24 completely inhibited the growth of colon cancer cells. CONCLUSION: We here provide evidence supporting conditionally replicative adenoviral vector-based gene therapy as a powerful strategy to enhance mda7/IL-24-dependent MDR reversion of colon cancer cells.
Authors: J W Pearson; W E Fogler; K Volker; N Usui; S K Goldenberg; E Gruys; C W Riggs; K Komschlies; R H Wiltrout; T Tsuruo Journal: J Natl Cancer Inst Date: 1991-10-02 Impact factor: 13.506
Authors: Andrew J Pellatt; Roger K Wolff; Jennifer Herrick; Abbie Lundgreen; Martha L Slattery Journal: Mol Carcinog Date: 2012-02-21 Impact factor: 4.784
Authors: Luni Emdad; Irina V Lebedeva; Zhao-zhong Su; Pankaj Gupta; Moira Sauane; Rupesh Dash; Steven Grant; Paul Dent; David T Curiel; Devanand Sarkar; Paul B Fisher Journal: Cancer Biol Ther Date: 2009-03-08 Impact factor: 4.742
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694
Authors: H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem Journal: Br J Cancer Date: 2006-05-30 Impact factor: 7.640
Authors: Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2018-03-02 Impact factor: 6.242
Authors: Lorenzo Cinci; Cristina Luceri; Elisabetta Bigagli; Ilaria Carboni; Sara Paccosi; Astrid Parenti; Daniele Guasti; Marcella Coronnello Journal: Cancer Med Date: 2016-03-25 Impact factor: 4.452
Authors: Q Wei; Z Ye; X Zhong; L Li; C Wang; R E Myers; J P Palazzo; D Fortuna; A Yan; S A Waldman; X Chen; J A Posey; A Basu-Mallick; B H Jiang; L Hou; J Shu; Y Sun; J Xing; B Li; H Yang Journal: Ann Oncol Date: 2017-09-01 Impact factor: 32.976